19P - High reduction of circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third...

Date 07 May 2015
Event IMPAKT 2015
Session Welcome reception and Poster Walk
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Metastatic
Translational Research
Presenter Luis Manso
Citation Annals of Oncology (2015) 26 (suppl_3): 6-9. 10.1093/annonc/mdv115
Authors L. Manso1, F. Moreno2, J.I. Delgado3, M.J. Echarri4, A. López5, Y. Izarzugaza6, P. Borrega7, N. Martínez8, C. Olier9, H. Cortes-Funes1
  • 1Clinical Oncology, University Hosptial 12 De Octubre, 28041 - Madrid/ES
  • 2Clinical Oncology, University Hospital Cíinico San Carlos, Madrid/ES
  • 3Clinical Oncology, Hospital Infanta Cristina, Badajoz/ES
  • 4Clinical Oncology, Hospital Severo Ochoa, Leganes/ES
  • 5Clinical Oncology, University Hospital of León, Leon/ES
  • 6Clinical Oncology, University Hospital "Fundacion Jimenez Diaz", Madrid/ES
  • 7Clinical Oncology, Hospital San Pedro de Alcántara, Cáceres/ES
  • 8Clinical Oncology, Hospital Universitario Ramon y Cajal, Madrid/ES
  • 9Clinical Oncology, HUFA Hospital Universitario Fundacion Alcorcon, Alcorcon/ES

Abstract

Body

Background: CTCs in peripheral blood are an ideal source for the detection of tumor dissemination. Their prognosis significance has been demonstrated in metastatic breast carcinoma (Cristofanilli, NEJM 2004). Eribulin (E) is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. Aims of this study are the evaluation of the prevalence and kinetics of CTCs before and after treatment with E in pts with MBC in third line.

Methods: Patients received E (1.23 mg/m2 on Days 1 and 8 of every 21-day cycle) as third-line therapy, until disease progression, unacceptable toxicity or withdrawal. CTCs were measured in 7.5ml of blood at baseline and after the first cycle of treatment and enumeration were performed by CellSearch System, Veridex LCC.

Results: Baseline CTCs data were available for 43 pts. The media value of baseline CTCs was 17 cells (min 0- max 21) and 6 cells (min 0-max 9) in second determination, p= 0,002. Baseline value of CTCs > 5 was presented in 38% of the pts and in 24% after first cycle, p = 0.035. After infusion of eribulin 60% of pts presented a CTCs value < 5. First follow-up was made in 26 pts after 3 months of treatment with CR 0%, PR 9% (n = 5), ED 21% (n = 11), PD 18% (n = 10). 55% (N = 10) of pts that had stable disease/partial response, decreased or maintained CTCs value < 5 post-treatment.

Conclusions: Our study suggests that treatment with eribulin in third line ABC was related with high and significant reduction of poor prognosis baseline value of CTCs >5 and CTCs counts.

Clinical trial identification: EudraCT 2013-001416-30

Disclosure: All authors have declared no conflicts of interest.